Citius Pharma CEO to present at two NYC investor conferences on new cancer drug LYMPHIR and pipeline progress

Citius Pharmaceuticals CEO Leonard Mazur will present and hold investor meetings at the 2026 Maxim Growth Summit and ThinkEquity Conference in New York City. He will discuss the company's business, including the commercialization of LYMPHIR, a targeted immunotherapy launched by Citius Oncology for certain lymphoma patients. The company also highlighted its late-stage pipeline products, Mino-Lok and Halo-Lido, both completing key clinical trials and awaiting FDA guidance. These presentations aim to update investors on Citius Pharma's growth and development strategy in critical care and oncology therapies.

Citius Pharmaceuticals (CTXR) trades at USD 0.49 on Pluang as of Oct 12, 2026 19:13 WIB, down 1.86% for the day. The company’s market cap stands at $13.71 million with a 52-week low of $0.48, showing the stock is near its lowest level in a year. This trading context accompanies CEO Leonard Mazur’s upcoming presentations at major investor conferences to discuss the company’s oncology and critical care pipeline.